Looking at a groundbreaking advance, Myovant gets a priority review at FDA; Agenus, G1 forge new China deals
→ Just weeks after posting promising pivotal results for relugolix in prostate cancer, Myovant has picked up a priority review from the FDA, which isn’t planning an expert committee review before making its decision. While much of the attention in this class is focused on uterine fibroids, an OK here would make this the first GnRH receptor antagonist treatment for men with advanced prostate cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.